Pinocembrin 7-apiosyl-(1->5)-apiosyl-(1->2)-glucoside



Compound IDCDAMM01204
Common namePinocembrin 7-apiosyl-(1->5)-apiosyl-(1->2)-glucoside
IUPAC name7-[3-[4-[[3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxyoxolan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-phenyl-2,3-dihydrochromen-4-one
Molecular formulaC31H38O17

Experimental data

Retention time18.72
Adduct[M+Na]+
Actual mz705.196
Theoretical mz705.2
Error6.55
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score6.0088

Identifiers and class information

Inchi keyOGHKMYABKJLKTL-IRTSWMLXNA-N
SmilesO=C1C2=C(O)C=C(OC3OC(CO)C(O)C(O)C3OC4OCC(O)(COC5OCC(O)(CO)C5O)C4O)C=C2OC(C=6C=CC=CC6)C1
SuperclassPhenylpropanoids and polyketides
ClassFlavonoids

Pharmacokinetic properties

Number of descriptor values(#stars)9
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)18
Number of reactive functional groups (#rtvFG)3
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)682.631
Computed dipole moment(dipole)8.067
Total solvent accessible surface area (SASA)948.643
Hydrophobic component of SASA (FOSA)383.935
Hydrophilic component of SASA (FISA)349.262
Pie component of the SASA (PISA)215.447
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)1851.39
Number of hydrogen bond donors (donorHB)8
Number of hydrogen bond acceptors (accptHB)23.45
Free energy of solvation of dipole (dip^2/V)0.035152
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0699173
Globularity descriptor (glob)0.768647
Predicted polarizability in cubic angstroms (QPpolrz)58.438
Predicted hexadecane/gas partition coefficient (QPlogPC16)21.315
Predicted octanol/gas partition coefficient (QPlogPoct)44.987
Predicted water/gas partition coefficient (QPlogPw)36.687
Predicted octanol/water partition coefficient (QPlogPo/w)-1.509
Predicted aqueous solubility (QPlogS)-2.761
Conformation-independent predicted aqueous solubility (CIQPlogS)-4.375
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-6.303
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)4.829
Predicted brain/blood partition coefficient (QPlogBB)-4.462
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)1.552
Predicted skin permeability, log Kp (QPlogKp)-5.469
PM3 calculated ionization potential (IP(ev))9.303
PM3 calculated electron affinity (EA(eV))0.333
Number of likely metabolic reactions (#metab)12
Prediction of binding to human serum albumin (QPlogKhsa)-1.49
Predicted qualitative human oral absorption (HumanOralAbsorption)1
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)0
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)262.746
Number of nitrogen and oxygen atoms (#NandO)17
Number of violations of Lipinski’s rule of five (RuleOfFive)3
Number of violations of Jorgensen’s rule of three (RuleOfThree)2

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
P11511CYP19A1Cytochrome P450 19A1T13260SwissTargetPrediction
P15692VEGFAVascular endothelial growth factor AT20761SEA
P05230FGF1Acidic fibroblast growth factorT18639SEA
P09038FGF2Basic fibroblast growth factorT31621SEA
P01112HRASTransforming protein p21/H-Ras-1T71081SEA
P60568IL2Interleukin-2T61698SEA
P17931LGALS3Galectin-3T72038SEA
P14679TYRTyrosinaseT97035SEA
Q16678CYP1B1Cytochrome P450 1B1T92521SEA
P16152CBR1Carbonyl reductase [NADPH] 1T70518SEA
Q9NZ08ERAP1Endoplasmic reticulum aminopeptidase 1T72849SEA
P30837ALDH1B1Acetaldehyde dehydrogenaseT99641SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T13260DI0062Breast cancer[ICD-11: 2C60-2C6Y]P11511CYP19A1
T13260DI0108Cushing syndrome[ICD-11: 5A70]P11511CYP19A1
T20761DI0095Colorectal cancer[ICD-11: 2B91]P15692VEGFA
T20761DI0365Retinopathy[ICD-11: 9B71]P15692VEGFA
T20761DI0430Vascular system developmental anomaly[ICD-11: LA90]P15692VEGFA
T18639DI0081Chronic arterial occlusive disease[ICD-11: BD4Z]P05230FGF1
T18639DI0102Coronary atherosclerosis[ICD-11: BA52]P05230FGF1
T31621DI0005Acne vulgaris[ICD-11: ED80]P09038FGF2
T61698DI0275Multiple sclerosis[ICD-11: 8A40]P60568IL2
T61698DI0361Renal cell carcinoma[ICD-11: 2C90]P60568IL2
T72038DI0190Hypertension[ICD-11: BA00-BA04]P17931LGALS3
T72038DI0199Idiopathic interstitial pneumonitis[ICD-11: CB03]P17931LGALS3
T72038DI0252Melanoma[ICD-11: 2C30]P17931LGALS3
T72038DI0302Non-alcoholic fatty liver disease[ICD-11: DB92]P17931LGALS3
T72038DI0351Psoriasis[ICD-11: EA90]P17931LGALS3
T97035DI0007Acquired hypermelanosis[ICD-11: ED60]P14679TYR
T97035DI0008Acquired hypomelanotic disorder[ICD-11: ED63]P14679TYR
T70518DI0037Asthma[ICD-11: CA23]P16152CBR1
T99641DI0396Substance abuse[ICD-11: 6C40]P30837ALDH1B1

Copyright © 2025